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Abstrak 
Setelah tercapainya banyak kemajuan dalam pengobatan penyakit infeksi bakteri dan 
virus, perkembangan terbaru di bidang medis saat ini adalah dengan ditemukannya banyak 
penyakit yang sebelumnya dikenal sebagai penyakit ‘idiopathic’ yang berarti ‘tidak diketahui 
penyebabnya’ sebagai penyakit-penyakit autoimmun. Kemajuan di bidang immunologi (ilmu 
kekebalan tubuh) dan penerapannya dalam berbagai penelitian telah menuntun kita kepada 
pengertian yang lebih mendalam dari patogenesa penyakit-penyakit autoimmune seperti 
contohnya pada Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), dan Immune / 
idiopathic Thrombocytopenia Purpura (ITP). Studi pustaka ini akan membahas peranan Fc 
Receptor (receptor untuk antibody yang dimiliki oleh sel-sel darah putih) pada khususnya Fc 
gamma Receptor, dalam patogenesis penyakit autoimmun. 
 
Kata kunci: FcR, autoimmune disease, inflammation 
 
 
 Introduction 
Immunoglubulins (anti-
bodies) are proteins found in the 
blood serum, which play pivotal 
roles in immunity. Despite their 
functions in host protection, in 
some circumstances immuno-
globulins are involved in the 
autoimmune process where au-
toantibodies may attack the host 
own tissue. A complex amal-
gamation of genetic predispo-
sitions together with the sur-
rounding environment influence 
is thought to cause the predis-
position of immune system dere-
gulation.  
Immunoglobulins are 
composed of two major func-
tional segments i.e. Fab (fraction 
‘antigen binding’) portion, and 
Fc (fraction ‘crystallizable’) por-
tion (see Fig. 1).  
 
 
Antigen binding 
Fab 
Fc
 
Figure 1. A schematic diagram of 
an immunoglobulin 
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While the Fab portion 
play the sole role in binding the 
antigen, such as antigens present 
on bacteria, viruses, or other an-
tigenic components, the Fc por-
tion encodes two of the ma-jor 
effector systems, i.e. activation 
of complement and activation of 
leukocyte specific cell surface 
receptors; known as Fc receptors 
(FcR). FcRs are membrane glyco-
proteins expressed on the sur-
face of inflammatory cells (i.e. 
macro-phages, neutrophils, den-
dritic cells, platelets, mast cells, 
NK cells, B cells, and certain 
subsets of T cells). 
In humans, there are five 
classes of immunoglobulin, call-
ed IgA, IgD, IgE, IgG, and IgM. 
Distinct cell membrane FcR have 
been described for all classes of 
immunoglobulin, including: 
FcαR (IgA), FcγR (IgG), FcεR 
(IgE), FcµR (IgM), and FcδR 
(IgD). The diversity of these 
receptors results in a wide va-
riety of biological responses, 
including: phagocytosis, endo-
cytosis, antibody-dependent cell 
mediated cytotoxicity, release of 
inflammatory mediators, regu-
lation of B cells activation, and 
antigen presentation. Moreover, 
with the fact that elevated IgG 
levels often found in the sera 
from patients suffered an auto-
immune disease, it has been 
suggested that FcγR involves 
and plays pivotal roles in the 
pathogenesis of the autoim-
munity. 
As the bridge between the 
humoral and cellular im-munity, 
FcγR is not only play a crucial 
role in the efferent mechanism 
which determine the fate of the 
FcγR bearing inflam-matory 
cells, but also in the afferent arm 
of immunity which direct the 
regulation of the anti-bodies 
produced. FcγR indeed influence 
the selection of epi-topes 
presented to T lympho-cytes. 
Thus, it is clear that further 
understanding of the ro-le of 
FcγR is necessary for a bet-ter 
knowledge for inflammation 
and autoimmune diseases pa-
thogenesis and therapy. This 
literature review will specifically 
discuss FcγR and its 
involvement in autoimmune 
diseases. 
 
 
Structural Diversity and 
Heterogeneity of Human FcγRs 
Recent advances have ex-
tensively characterized mouse 
and human FcγRs. Three distinct 
classes of human FcγR are cur-
rently recognized: FcγRI, FcγRII, 
and FcγRIII (Tan Sardjono et al. 
2003). These classes are based on 
the basis of a number of sero-
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including their cell distribution, 
molecular size and recognition 
by monoclonal antibodies 
(Hogarth 2002). The most im-
portant factor that distinguishes 
the FcγRs classes is their dif-
ference in the affinity to IgG. 
FcγRI, the high affinity receptor, 
is able to bind monomeric IgG 
with high affinity. In contrast, 
FcγRII and FcγRIII the low af-
finity receptors, bind monomeric 
IgG poorly with a measurable 
affinity of less than 107 M-1 and 
preferentially bind to complexed 
IgG (Hogarth 2002). Moreover, 
there are differences among the 
FcγRs in the preference IgG 
subclasses binding. The 
diversity and similarity among 
human FcγRs are described 
below and summarized in Table 
1.  
Human FcγRI (CD64), is 
a 72kDa glycoprotein which 
contains three extracellular Ig-
like domains that bind mono-
meric IgG with high affinity 
(Hogarth 2002). The first two 
 
 
Table 1. Human IgG receptors
FcγRI (CD64)
FcγRIa FcγRIIa FcγRIIb FcγRIIIa FcγRIIIb
< 107 M-1
=3>>>2=4
2a>2b>>1
I-anchored
-
utrophils,
NK cells
6)
Molecular weight 72 kDa
Chromosome 1q21.1 1q23 - 24 1q23 - 24
Ig-like domains 3
Affinity for monomeric IgG 108 - 109 M-1 2 x 107 M-1
Specificity for human IgG 3>1>4>>>2 His134: 3>1=2>>>4 3>1>4>2 *ND 1
Arg134: 3>1>>2,4
                     mouse IgG 2a=3>>>1,2b His134: 2a=2b>>1 2a=2b>1 3>2a>2b>1 3>
Arg134: 2a=2b=1
Receptor form transmembrane transmembrane transmembrane transmembrane GP
Signalling motif †ITAM †ITAM ‡ITIM †ITAM
Signalling subunits γ - - γ
Cellular distribution monocytes, monocytes, monocytes, macrophages, ne
macrophages, macrophages, macrophages, NK cells,
blood dendritic cells, neutrophils, B cells, γδ T cells
neutrophils eosinophils, mast cells neutrophils (mouse)
platelets, neutrophils, mast cells
dendritic cells, dendritic cells,
mast cells mast cells
Langerhans cells
*ND = Not Determined
†ITAM = Immunoreceptor Tyrosine-Based Activation Motif
‡ITIM = Immuno receptor Tyrosine-Based Inhibition Motif
FcγRII (CD32) FcγRIII (CD1
< 107 M-1
40 kDa 50 - 80 kDa
1q23 - 24
22
 
 
 51
 
JKM. 
Vol. 4, No.1, Juli 2004 
 
extracellular domains of FcγRI 
are homologous to FcγRII and 
FcγRIII (Fig. 2), while the third 
domain is distinctive to FcγRI 
(Hogarth 2002). Several studies 
of human and mouse FcγRI 
showed that the interaction of 
the second and the third extra-
cellular domain of FcγRI is cru-
cial in determining the high 
affinity of this receptor (Hogarth 
2002).  Human FcγRI (hFcγRI) 
preferentially binds hIgG1 and 
hIgG3 with higher affinity com-
pared to hIgG4 and hIgG2 
(Hogarth 2002). 
  Human FcγRII (CD32), is 
a low affinity receptor for IgG 
with molecular weight of 40kDa 
(Tan Sardjono et al. 2003). FcγRII 
expressed on the most abundant 
cellular distribution, including 
neutrophils, eosinophils, B lym-
phocytes, platelets, mast cells, 
Langerhans cells, placental en-
dothelial cells, and dendritic 
cells. Several isoforms of human 
FcγRII have been identified by 
molecular cloning, i.e. FcγRIIa1, 
FcγRIIa2, FcγRIIb1, FcγRIIb2, 
FcγRIIb3, and FcγRIIc (Tan 
Sardjono et al. 2003). With the 
exception of hFcγRIIa2, a pos-
sible soluble form of FcγRIIa, 
FcγRII isoforms are membrane-
bound glycoproteins, with two 
extracellular Ig-like domains, a 
transmembrane domain, and a 
cytoplasmic domain (see Fig.2).  
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Figure 2. Human FcγRs (huFcγRs) and associated signalling molecules FcR γ and ζ sub-unit.
D1, D2, D3 indicate domains 1, 2, and 3; GPI indicate the GPI-anchored transmembrane domain
(+) indicate the activatory ITAM motif
(-) indicate the inhibitory ITIM motif
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The extracellular domains 
of FcγRII are highly conserved, 
al-though the transmembrane 
and cytoplasmic domains of 
FcγRII show a significant diver-
sity, including the different sig-
nals in the cellular mediated 
response. FcγRIIa can act inde-
pendently from the FcR γ-chain 
(a signaling molecule associated 
with FcγRI and FcγRIII) and the 
other FcγRs, where stimulation 
of FcγRIIa alone is sufficient to 
mediate a phagocytic signal 
(Indik et al. 1991). 
FcγRIII (CD16) is a low 
affinity receptor for IgG with 
molecular weight of 50-80kDa 
(Hulett and Hogarth 1994). Two 
isoforms of FcγRIII have been 
identified based on their dif-
ferent transmembrane domain. 
Whereas FcγRIIIa has a trans-
membrane domain similar to the 
other FcγRs family, FcγRIIIb is a 
GPI-anchored receptor which 
lacked of cytoplasmic domain 
(see Figure 2 and Table 1) 
(Hogarth 2002). FcγRIIIa which 
is expressed on human mono-
cytes, macrophages, NK cells, 
mast cells, and γδ T cell subset, is 
a cell-type-specific glycosylated 
transmembrane protein, which 
at different cell type, this recep-
tor requires different type of 
associated molecule for its 
function (Hulett and Hogarth 
1994). Such as on macrophages, 
FcγRIIIa requires the association 
with FcR γ-chain subunit for its 
expression, whereas on NK cells 
it requires the association with 
homo- and or hetero-dimers of 
the FcR γ-chain subunit and the 
CD3 TCR complex ζ-subunit 
(Hulett and Hogarth 1994). Seve-
ral polymorphic variants found 
in FcγRIIIa are also associated 
with autoimmunity. The Val 158 
allelic variant of FcγRIIIa has a 
higher affinity for hIgG1 and 
hIgG3, compared to the Phe158 
variant. Individuals with the 
homozygote FcγRIIIa 158Phe/ 
Phe is proposed to be more 
susceptible to SLE and Rheuma-
toid Arthritis (Koene et al. 1998; 
Nieto et al. 2000). The reason for 
this predisposition has been 
suggested that inefficient clear-
ance of circulating or tissue-
deposited immune complexes 
may involve in the initiation of 
the disease (Takai 2002). 
FcγRIIIb expression is restricted 
to netro-phils and NK cells and 
it is fixed to the cell membrane 
by a GPI-anchor protein 
(Hogarth 2002). Due to the lack 
of its cyto-plasmic tail, signal 
transduction following 
engagement of FcγRIIIb to its 
ligand occurs via associated 
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transmembrane pro-teins such 
as complement recep-tor type 3 
(CR3) or through FcγRIIa (Hulett 
and Hogarth 1994). FcγRIIIb on 
neutrophils does not directly 
mediated pha-gocytosis of IgG-
coated parti-cles, but contributes 
in the sec-retion of toxic 
products in response to immune 
complexes and in the actin 
filament assem-bly (Hulett and 
Hogarth 1994). Human FcγRIIIb 
has a structural polymorphism 
which differs in five base 
substitutions resulting in four 
amino acid substitution in the 
extracellular domain. The 
corresponding polymorphic gly-
coproteins are termed neutro-
phil antigen 1 (NA1) and 2 
(NA2). In SDS-PAGE analysis,  
NA1 has a molecular weight 
ranging between 50-65kDa and 
65-80kDa for NA2 due to two 
glycosy-lation sites in NA1 and 
four NA2 (Huizinga et al. 1990). 
Several forms of autoimmune 
disease are associated with the 
NA polymorphisms, such as in 
SLE (Yap et al. 1999), auto-
immune neutropenia in infancy 
(Taniuchi et al. 2001), systemic 
vasculitis (Tse et al. 2000), 
Guillain - Barre Syndrome 
(Vedeler et al. 2000), and Mul-
tiple Sclerosis (Myhr et al. 1999). 
Although hFcγRIII is a low 
affinity receptor, there is a slight 
variation in the affinity for 
monomeric IgG between FcγRIII 
isoforms. Human FcγRIIIb (the 
GPI-anchored isoform) has an 
affinity with Ka < 107 M-1 and 
the FcγRIIIa isoform has a mode-
rately higher affinity with Ka = 2 
x 107 M-1 (Hulett and Hogarth 
1994). Human FcγRIIIb prefer-
entially binds hIgG3 and hIgG1 
but not hIgG2 or hIgG4 com-
plexes (Hulett and Hogarth 
1994). Whereas human hFcγRIIIa 
specificity has not been deter-
mined (Hulett and Hogarth 
1994). 
 
 
Regulation of FcγRs signaling 
FcγRIIa cytoplasmic do-
main contains an Immunorecep-
tor Tyrosine-based Activa-tory 
Motif (ITAM) (see Fig. 2), which 
originally observed in the cyto-
plasmic domains of several other 
receptor families, including the 
B-cell receptor (Tan Sardjono et 
al. 2003). This ITAM motif is 
responsible for the activatory 
signal transduced, which deter-
mine the cell’s activation status 
to perform endocytosis and 
phagocytosis of the immune 
complexes or to subsequently re-
lease inflammatory mediators 
(Tan Sardjono et al. 2003). The 
FcγRIIa ITAM motif is consisted 
of two copies of YxxL (where x 
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denotes any amino acid) repeats 
separated by 12 amino acids, 
that the tyrosines (Y) within the 
motif are phosphorylated after 
receptor crosslinking (Tan 
Sardjono et al. 2003). The activ-
atory receptors other than 
FcγRIIa, i.e. FcγRI, FcγRIII, FcεRI 
and FcαRI rely on the FcR γ-
chain for signal transduction 
(Hulett and Hogarth 1994) (see 
Fig 2). The FcR γ-chain bears an 
ITAM responsible for the re-
cruitment activatory tyrosine 
kinases which followed by cal-
cium mobilization and subse-
quently result in the cell activ-
ation (Hulett and Hogarth 1994).  
In contrast, FcγRIIb cyto-
plasmic domain contains an 
ITIM (Immunoreceptor Tyro-
sine-based Inhibitory Motif) 
which has a restricted consensus 
sequence of single V/IxYxxL/V 
(YSLL) sequence, where phos-
phorylation of the tyrosine on 
this motif result in the inhibitory 
activity of this receptor through 
the recruitment of inhibitory 
signaling molecules (Hulett and 
Hogarth 1994). Co-engagement 
of ITIM bearing molecules such 
as FcγRIIb to an ITAM contain-
ing receptor (either through the 
signalling molecule γ-chain, or to 
FcγRIIa), leads to tyrosine phos-
phorylation of the ITIM results 
in the inhibition ITAM-triggered 
calcium mobilization which inhi-
bits cellular proliferation (Hulett 
and Hogarth 1994). Whereas 
homoaggregation of FcγRIIb on 
B cells has been shown to induce 
cell apoptosis (Hulett and 
Hogarth 1994). 
 
 
Function and regulation of Fcγ 
receptors 
Fc receptors provide the 
bridge between humoral and 
cellular immunity that are cru-
cial to the regulation of immune 
system to protect against foreign 
organisms. Upon their inter-
action with IgG, the activating 
FcγRs, initiate phagocytosis, 
antibody-dependent cellular 
cytotoxicity (ADCC), transcrip-
tion of cytokines genes, and 
release of inflammatory media-
tors (Tan Sardjono et al. 2003). 
Moreover FcγRs play an im-
portant role in the opsonization 
of antigens, which in the antigen 
presentation process determine 
specific epitopes of the antibody 
produced (Tan Sardjono et al. 
2003). Antigen-IgG complexes 
that are processed via FcγRs 
undergo a more efficient MHC 
class I and class II-restricted an-
tigen presentation in DCs which 
result on the enhanced antibody 
production by B cells induced by 
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Mechanisms of antibody-
mediated inflammation are sum-
marized in a schematic diagram 
presented in Figure 3.  
 
 
FcγRs in Disease and Therapy 
Deposition of immune 
complexes, often as a result of 
autoantibodies production a-
gainst self antigens may lead 
into tissue damage and organs 
destruction. There has been an 
extensive interest in FcγR in the 
some autoimmune inflammation 
diseases such as Systemic Lupus 
Erythematosus (SLE) 
(Dijstelbloem et al. 2000), Rheu-
matoid Arthritis (RA) (Blom et 
al. 2000), Good Pasteur’s syn-
drome (Nakamura et al. 2000), 
APC 
T
B
Antibody  
secretion 
Complement 
fixation 
Phagocytosis 
ADCC 
Target cell lysis Release of  
inflammatory mediators  
e.g. TNF- α, interleukins, etc 
Antigen 
re-presentation 
• Opsonization 
FcγR • Membrane 
 attack 
complex
Inflammation
 Figure 3 An antigen recognition process is initiated by a antigen presenting cell to the T 
 presentation of an antigen by the cells, which induces the B cell  maturation and proliferation 
to secrete a specific antibody against the antigen. The antigen antibody complexes result in  
the form of immune complexes which induce the complement activation or/and Fc- Rγ mediated-
cell activation The consequence of this progression is inflammation
(Tan Sardjono et al. 2003). 
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Immune Thrombocytopenia 
(ITP) (McKenzie 2002), and in 
(Heparin-Induced Thrombosis 
and Thrombocytopenia Syn-
drome (HITTS) (Reilly et al. 
2001). 
Several autoimmune di-
seases often correlated with the 
antibody-mediatedinflammation 
and therefore possible FcγRs 
involvements are discussed as 
follow: 
 
 
Rheumatoid Arthritis 
Rheumatoid arthritis 
(RA) is the most frequent sys-
temic and chronic inflammatory 
disease, characterize by a chro-
nic synovitis which often results 
in joint destruction. RA affects 
more than 1% of general po-
pulation worldwide and results 
in more than 250,000 hos-
pitalizations per year (Hochberg 
and Spector 1990). Despite the 
evidence of multifactorial pre-
disposition to the severity of the 
disease the class II major his-
tocompatibility (MHC) loci, 
polymorphism of cytokines, RF 
specific genes, post infection, 
and environmental factors, it has 
been suggested that antibody 
plays an important role in the 
pathogenesis of RA (Tan 
Sardjono et al. 2003). As the 
receptors for IgG, FcγRs thus 
provide the bridge between the 
humoral and cellular activity. It 
has been shown in mouse mo-
dels of Rheumatoid Arthritis i.e. 
in anti-GPI antibody-induced 
arthritis, experimental immune 
complex-mediated arthritis 
(ICA), and in the Collagen-
Induced Arthritis (CIA), have 
shown the importance of FcγRs, 
as mice with lacked FcγRs were 
protected from the disease (Tan 
Sardjono et al. 2003).  
 
 
Systemic Lupus Erythematosus 
Systemic Lupus Erythe-
matosus (SLE) represents an 
immune complex-mediated au-
toimmune disease, involving 
multiple organs inflammation, 
with clinical manifestations in-
cluding non-invasive arthritis, 
vasculitis, glomerulonephritis, 
and lung inflammation. In hu-
man SLE, several genes have 
been suggested to contribute to 
SLE susceptibility and it has 
been estimated that 25-30 diffe-
rent gene loci may contribute to 
the increased risk for SLE 
(Wakeland et al. 1999). Sle1 locus 
has been shown to be associated 
with the loss of tolerance against 
chromatin with a preferential 
target of Histones/DNA com-
plex (Morel et al. 2001). Sle1 was 
mapped to chromosome 1 in 
mouse which in humans is equi-
valently located to chromosome 
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1q21-44. More interestingly, this 
region (chromosome 1q21-44) is 
also encodes several genes for 
inflammatory-associated mole-
cules, such as FcγRs, FcR γ-chain, 
and Serum Amyloid P (SAP), 
which have been suggested to 
also play a role in SLE sus-
ceptibility (Bickerstaff et al. 1999; 
Wu et al. 1997).  
Several autoantibodies 
have been correlated with the 
disease pathogenesis and pro-
gression, these antibodies are 
including anti-dsDNA, anti-
Smith antigen (anti-Sm), anti-
histones, anti-ssDNA, anti-RNP, 
anti-Ro/SSA, anti-La/SSB, anti-
PCNA, anti-Ku, anti-Lamin B, 
and anti-Ribosomal P (anti-RNP) 
(Reeves 1992). Various studies 
have shown a strong indication 
for the importance FcγRs 
polymorphisms for suscepti-
bility to SLE. The most studied 
polymorphism of FcγRIIa in-
volves in the substitution of 
Arginine at position 134 
(Arg134) or Histidine at position 
134 (His134), which located 
within the ligand binding site. 
The FcγRIIa containing His134 
exhibits a higher ability to bind 
complexed human IgG2, but 
lower for complexed IgG3 
(Hogarth 2002). In a study on 
African-American and Dutch 
SLE patients,  the Arg/Arg134 
genotype was more commonly 
found in patients which deve-
loped nephritis SLE (van der Pol 
and van de Winkel 1998), which 
may suggest the importance of 
the FcγRIIa polymorphism to 
increased susceptibility of SLE 
and type of outcome of the 
disease. Another polymorphim 
of human FcγR that may involve 
in the susceptibility or to the 
type of SLE manifestation is the 
polymorphism FcγRIIIa. Substi-
tution of Phenylalanine at posi-
tion 158 (Phe158) to Valine 158 
(Val158) of huFcγRIIIa result in a 
greater avidity to bind human 
IgG1, IgG3 and IgG4 subclasses 
(Edberg et al. 2002). The poly-
morphism in FcγRIIIb of neu-
trophils (NA1 or NA2) involving 
four amino acid substitutions, 
FcγRIIIb-NA1, which is more 
efficient in binding immune 
complexes containing IgG1 and 
IgG3 than the FcγRIIIb-NA2 
form (Edberg et al. 2002). These 
polymorphisms have been 
suggested to influence the SLE 
manifestation rather than the 
occurrence of the disease. 
 
 
Glomerulonephritis in SLE 
 Although multiple or-
gans are often involved in active 
SLE, kidney is the most com-
monly affected organ. While on-
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ly approximately 50% of patients 
develop clinically evident renal 
disease, results of kidney biopsy 
demonstrate some degree of 
renal involvement in almost all 
patients with SLE (Reeves 1992). 
Deposition of autoantibodies in 
tissues and organs subsequently 
induces the inflammatory res-
ponse which may result from ac-
tivation of resident tissue in-
flammatory cells and/or re-
cruitment of circulating mono-
cytes or neutrophils to sites of 
deposition (Tan Sardjono et al. 
2003). The actual mechanism of 
the glomerulonephritis in SLE is 
not totally understood, however 
there are three basic hypo-
thetical mechanisms of by which 
anti-bodies can cause nephritis 
i.e. (i) deposition of circulating 
immune complexes, (ii) anti-
body cross reactivity with kid-
ney antigen, (iii) planted antigen 
(Tan Sardjono et al. 2003). The 
first hypothesis was based on 
the theory that the autoanti-
bodies form circulation immune 
complexes that bind to glome-
rulus, whereas in the second 
hypothesis, the cross reactivity 
of antibody that may bind to 
antigens present on the glome-
rulus such as the basal mem-
brane components. The third 
hypothesis, was by modeled by 
antigens deposited in the glome-
rulus, such as histones, may 
subsequently trap circulating an-
tibodies. Despite their differen-
ces, these three possible mecha-
nisms may all mutually contri-
bute to the pathogenesis of the 
disease. The ability of histone to 
bind collagen type IV and hepar-
in sulphate proteoglycan in the 
basement membrane in the glo-
meruli demonstrates a possible 
role of anti-histone antibody in 
the pathogenesis of SLE (Tan 
Sardjono et al. 2003).  
 
 
Pneumonitis in SLE 
Beside the skin inflam-
mation and glomerulonephritis, 
lung inflammation is also often 
found in SLE. In some studies, 
FcγRs were showed to be res-
ponsible for initiating the in-
flammatory response. The FcγRs 
bearing inflammatory cells are 
likely to be the local alveolar 
macrophages (Tan Sardjono et 
al. 2003), which elaborate several 
inflammatory mediators that 
augment the tissue injuries 
event.  
 
 
Immune Thrombocytopenia 
Purpura 
Immune Thrombocytope-
nia Purpura (ITP) is a disorder 
where platelets are depleted by 
autoantibodies against a variety 
of proteins on platelets surface, 
 
JKM. 
Vol. 4, No.1, Juli 2004 
 60
most notably against gpIIb/IIIa 
(McKenzie 2002). The IgG with 
specificity for one or more pla-
telet membrane glycoproteins, 
binds to circulating platelet 
membranes results in splenic 
sequestration and phagocytosis 
by mononuclear macrophages 
through FcγR. The resulting 
shortened life span of platelets 
in the circulation together with 
incomplete compensation by in-
creased platelet production by 
bone marrow megakaryocytes 
results in a decreased platelet 
count. The role of FcγRs in this 
disorder was demonstrated in 
the mice deficient for the FcR γ-
chain subunit, which lacked 
FcγRI and FcγRIIIa function to be 
protected from the ITP in-
duction (McKenzie 2002). The 
importance of FcγRIIa in the pa-
thogenesis of ITP has been stu-
died by using the FcγRIIa trans-
genic mice, and FcγRIIa was 
found to be crucial in the deve-
lopment of ITP (McKenzie 2002).  
 
 
 
Heparin-Induced Thrombosis 
and Thrombocytopenia 
Syndrome 
Heparin-Induced Throm-
bosis and Thrombocytopenia 
Syndrome (HITTS) is the most 
common drug-induced immune 
thrombocytopenia that occurs in 
1% to 3% of patients exposed to 
heparin (Reilly et al. 2001). He-
parin treatment can induce the 
production of antibodies with 
neo-epitope that recognise a 
complex of heparin and Platelet 
Factor 4 (PF4) (Reilly et al. 2001). 
Antibodies to a neo-epitope in 
the complex interact both with 
the antigen and with the FcγRIIa 
on platelet to trigger platelet 
activation leading to thrombosis 
and thrombocytopenia (Reilly et 
al. 2001). FcγRIIa as the only IgG 
Fc receptor on human platelets 
has been shown to play an 
important role in the disease 
pathogenesis and manifestation 
(Reilly et al. 2001).  
 
 
Concluding Comments 
Certainly, a complex com-
bination of multifactor within 
the immune system plays a 
concert in the immune response. 
Genetic predisposition and envi-
ronmental aspect influence the 
occurrence and pathogenesis of 
autoimmune disease. However, 
advanced studies of FcγRs have 
revealed the FcγRs crucial roles 
in both efferent and afferent of 
immune response which leads to 
inflammation and that blockade 
of FcγRs is a potentially useful 
approach for therapy of many 
cases of autoimmune diseases.  
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